This inventor holds 1 USPTO granted patent. Top assignee: Atea Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Adel Moussa: Innovator in SARS-CoV-2 Therapy
Introduction
Adel Moussa is a prominent inventor known for his contributions to the field of pharmaceutical innovations. He has made significant strides in developing therapies aimed at combating viral infections, particularly those caused by SARS-CoV-2.
Latest Patents
Adel Moussa holds a patent for "NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY." This innovative approach addresses the challenges posed by mutant strains of the virus, showcasing his commitment to advancing medical science.
Career Highlights
Moussa is currently associated with Atea Pharmaceuticals, Inc., where he continues to work on groundbreaking research and development projects. His expertise in drug development has positioned him as a key player in the fight against viral diseases.
Collaborations
Throughout his career, Adel Moussa has collaborated with notable professionals in the field, including Jean-Pierre Sommadossi and Kai Lin. These partnerships have enhanced the scope and impact of his research efforts.
Conclusion
Adel Moussa's work in developing therapies for SARS-CoV-2 demonstrates his dedication to innovation in the pharmaceutical industry. His contributions are vital in the ongoing battle against viral infections, and his patent reflects his significant role in this critical area of research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile